Balyasny Asset Management
VKTX icon

Balyasny Asset Management’s Viking Therapeutics VKTX Stock Holding History

Balyasny Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,300
Closed -$369K – 3396
2025
Q1 		$369K Sell
15,300
-9,700
-39% -$307K ﹤0.01% 2377
2024
Q4 		$1.01M Sell
25,000
-2,300
-8% -$131K ﹤0.01% 1948
2024
Q3 		$1.73M Buy
+27,300
New +$1.6M ﹤0.01% 1731

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management's VKTX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 36,493 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2011 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in VKTX as recently as Q1 2025.

Balyasny Asset Management first reported a position in VKTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $41.8M in Q4 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Balyasny Asset Management held 36,493 shares of Viking Therapeutics worth $1.19M as of Q1 2026.
  • Viking Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2011 holding.
  • Balyasny Asset Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • Balyasny Asset Management's Viking Therapeutics position peaked at $41.8M in Q4 2023.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.